Insulin delivery company Insulet Corporation (NASDAQ: PODD) will be reporting earnings this Wednesday morning. Here’s what you need to know.
Insulet beat analysts’ revenue expectations last quarter, reporting revenues of $761.7 million, up 33.9% year on year. It was a very strong quarter for the company, with a beat of analysts’ EPS estimates.
Is Insulet a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting Insulet’s revenue to grow 21.3% year on year, slowing from the 32.9% increase it recorded in the same quarter last year.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Insulet has a history of exceeding Wall Street’s expectations.
Looking at Insulet’s peers in the healthcare equipment and supplies segment, some have already reported their Q2 results, giving us a hint as to what we can expect. DexCom delivered year-on-year revenue growth of 13.1%, beating analysts’ expectations by 1.4%, and Baxter reported revenues up 5.3%, topping estimates by 6%. DexCom traded up 12% following the results while Baxter was also up 5.6%.
Read our full analysis of DexCom’s results here and Baxter’s results here.
Investors in the healthcare equipment and supplies segment have had steady hands going into earnings, with share prices up 1.9% on average over the last month. Insulet is up 6.2% during the same time and is heading into earnings with an average analyst price target of $235.54 (compared to the current share price of $169.65).
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.
